Ten percent of patients abandon newly initiated oral oncolytics at the pharmacy. Patients facing higher cost sharing or increased concurrent prescription activity have a higher abandonment rate.
Sonya Blesser Streeter, MPP, MPH
Advertisement
Articles by Sonya Blesser Streeter, MPP, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
2
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
3
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
4
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
5